Landscape of immunotherapeutic targets in sarcoma

Immunotherapy has emerged as a promising modality for the treatment of cancer and is designed to tip the balance from tumor immune evasion to an effective anti-tumor immune response. Major immunotherapeutic approaches are immune checkpoint inhibition, neoantigen-based peptide vaccination as well as adoptive cell transfer (ACT) based on T-cell receptors (TCRs; MHC-restricted) or chimeric antigen receptors (CARs; non-MHC-restricted) that target tumor-associated antigens (TAA) derived from cancer testis antigens (CTA), neoantigens or cancer germline antigens. Studying tumor-intrinsic pathways and immunoregulatory proteins expressed on tumors and their interactions with tumor immune microenvironment can unveil disease mechanisms and inform the choice of effective immunotherapeutic strategy. Our group is combining multi-omics-based immune profiling of tumors with multiplex immunohistochemistry, mass spectrometry and in vitro immune-assays to uncover the immune evasion strategies of tumors and enable systematic discovery of immunotherapeutic targets.

© DKFZ

to top
powered by webEdition CMS